Analysis of cumulative probabilities shows that the efficacy of 5HT(3) antagonist prophylaxis is not maintained

被引:36
作者
deWit, R
Schmitz, PIM
Verweij, J
deBoerDennert, M
deMulder, PHM
Planting, AST
vanderBurg, MEL
Stoter, G
机构
[1] ROTTERDAM CANC INST,DANIEL DEN HOED KLIN,DEPT MED STAT,3075 EA ROTTERDAM,NETHERLANDS
[2] UNIV NIJMEGEN,ACAD HOSP,DEPT MED ONCOL,NIJMEGEN,NETHERLANDS
关键词
D O I
10.1200/JCO.1996.14.2.644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Several investigators have reported that the efficacy of 5HT(3) receptor antagonists is maintained over repeated cycles of chemotherapy. These investigators presented conditional probabilities of protection. Because conditional analyses by definition only include patients with protection in previous cycles, the results are flattered. Patients and Methods: We applied a novel statistical approach to investigate whether the efficacy of the 5HT(3) receptor antagonist ICS 205-930 (tropiseltron) is maintained over repeated cycles of weekly high-dose cisplatin. Overall protection was determined based on cumulative probabilities with the Kaplan-Meier method. Complete protection was calculated with a three state model for transitional probabilities. Eighty-three patients were studied. Results: Over six consecutive cycles, protection against both acute and delayed emesis decreased significantly. The initial complete and overall protection rates against acute emesis of 71% and 95%, respectively, decreased to 43% and 72% in the sixth cycle of chemotherapy, Similarly, the protection rates of 31% and 68% against delayed emesis decreased to 6% and 40%, respectively. Conclusion: We conclude that overall and complete long-term protection is more accurately measured by cumulative probabilities than with a method that is based on conditional probabilities. Our statistical approach shows that the efficacy of 5HT(3) antagonists is not maintained. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:644 / 651
页数:8
相关论文
共 25 条
[1]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[2]  
BLIJHAM G H, 1992, European Journal of Cancer, V28A, pS17, DOI 10.1016/0959-8049(92)90631-B
[3]   ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].
COATES, A ;
ABRAHAM, S ;
KAYE, SB ;
SOWERBUTTS, T ;
FREWIN, C ;
FOX, RM ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208
[4]   Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting - A Multicenter, Randomized, Double-Blind, Crossover Study [J].
Demulder, PHM ;
Seynaeve, C ;
Vermorken, JB ;
Vanliessum, PA ;
Molsjevdevic, S ;
Allman, EL ;
Beranek, P ;
Verweij, J .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (11) :834-840
[5]  
DEWET M, 1993, CANCER, V71, P4043, DOI 10.1002/1097-0142(19930615)71:12<4043::AID-CNCR2820711239>3.0.CO
[6]  
2-A
[7]  
GANDARA DR, 1992, SEMIN ONCOL, V19, P67
[8]   A SINGLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON, A SELECTIVE SEROTONIN ANTAGONIST, WITH INTRAVENOUS METOCLOPRAMIDE IN THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE CISPLATIN CHEMOTHERAPY [J].
HAINSWORTH, J ;
HARVEY, W ;
PENDERGRASS, K ;
KASIMIS, B ;
OBLON, D ;
MONAGHAN, G ;
GANDARA, D ;
HESKETH, P ;
KHOJASTEH, A ;
HARKER, G ;
YORK, M ;
SIDDIQUI, T ;
FINN, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) :721-728
[9]  
HAMILTON LC, 1992, REGRESSION GRAPHICS, P313
[10]  
INGELFINGER JA, 1983, BIOSTATISTICS CLIN M, P10